Skip to content
10-Q

Quarterly Report

Tevogen Bio Holdings Inc. TVGN TVGNW

0001493152-26-023920

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 4.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 3.49M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 3.23M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.31M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$9.84M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$8.23M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$7.72M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$6.67M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.27M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.07M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.76M
Total Liabilities Q1 2026 · Dec 31, 2025 $12.62M
Current Assets Q1 2026 · Mar 31, 2026 $2.14M
Current Assets Q1 2026 · Dec 31, 2025 $1.54M
Total Assets Q1 2026 · Mar 31, 2026 $4.92M
Total Assets Q1 2026 · Dec 31, 2025 $4.38M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.61
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$3.25
Eps Basic Q1 2026 · Mar 31, 2026 −$1.61
Eps Basic restated Q1 2026 · Mar 31, 2025 −$3.25
Sga Expense Q1 2026 · Mar 31, 2026 $2.27M
Sga Expense Q1 2026 · Mar 31, 2025 $7.16M
Rd Expense Q1 2026 · Mar 31, 2026 $3.13M
Rd Expense Q1 2026 · Mar 31, 2025 $3.2M
Net Income Q1 2026 · Mar 31, 2026 −$5.45M
Net Income Q1 2026 · Mar 31, 2025 −$10.37M
Operating Income Q1 2026 · Mar 31, 2026 −$5.4M
Operating Income Q1 2026 · Mar 31, 2025 −$10.36M